- Home
- GSIW vs BCTX Comparison
GSIW vs BCTX Comparison
Compare GSIW & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GSIW | BCTX |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | Hong Kong | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5M | 28.8M |
| IPO Year | 2022 | 2025 |
Fundamental Metrics
Financial Performance| Metric | GSIW | BCTX |
|---|---|---|
| Price | $30.30 | $4.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 3.6K | ★ 134.9K |
| Earning Date | 08-04-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $380.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.05 | $0.61 |
| 52 Week High | $36.90 | $14.68 |
Technical Indicators
Market Signals| Indicator | GSIW | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 82.72 | 45.11 |
| Support Level | $0.11 | $3.66 |
| Resistance Level | $36.90 | $4.51 |
| Average True Range (ATR) | 1.43 | 0.27 |
| MACD | 0.80 | 0.00 |
| Stochastic Oscillator | 95.57 | 20.83 |
Price Performance
Historical ComparisonAbout GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.